Bextra Arthritis Drug Publications
The following publications on the arthritis drug Bextra has been provided by the U.S. Food and Drug Administration, public interest groups, and Weitz & Luxenberg, PC.
• Bextra Labeling: Includes documents describing the clinical pharmacology, NDC codes with respective trade names, and current product label.
• FDA Bextra Letters: These are letters from the FDA issuing warnings and safety alerts.
• FDA Bextra Warnings: These are warnings from the manufacturer and FDA signifying warnings concerning the use of the drug Bextra.
• FDA Public Comments: This section includes comments from the public about the drug Bextra.
Weitz & Luxenberg is no longer accepting Bextra cases.
see also:
Public Comments
Public Comments on Possibility of Bextra LawsuitSome of these comments may have bearing on your Bextra lawsuit.
Labeling
Arthritis Drug Bextra Labeling informationofficial documents on the labeling of the arthritis drug Bextra
About the Bextra Recall
Bextra lawyers - about the FDA Bextra recallBextra Withdrawal: Letter to clients about the FDA Bextra recall
